BiotechTube

AZD5213 and placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tourette Syndrome

Conditions

Tourette Syndrome

Trial Timeline

Aug 1, 2013 → Feb 1, 2015

NCT ID
NCT01904773

About AZD5213 and placebo

AZD5213 and placebo is a phase 2 stage product being developed by AstraZeneca for Tourette Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01904773. Target conditions include Tourette Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01904773Phase 2Completed

Competing Products

12 competing products in Tourette Syndrome

See all competitors
ProductCompanyStageHype Score
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
51
AripiprazoleBristol Myers SquibbPre-clinical
22
NBI-98854Neurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 1
30
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Abobotulinum toxin AIpsenPre-clinical
20
Tetrabenazine MR + PlaceboBausch HealthPhase 2
47

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85